title: T-status and an oral fluoropyrimidine, S-1, adjuvant chemotherapy are prognostic factors in reduced-RADPLAT for resectable hypopharyngeal cancer.
abstract: CONCLUSIONS
  Reduced-RADPLAT for HPC achieved comparative survival and locoregional control rates with lower toxicities compared with concurrent chemoradiotherapies including original RADPLAT. S-1 adjuvant chemotherapy showed a survival benefit.
  
  
  OBJECTIVE
  To evaluate the efficacy and toxicities of targeted intra-arterial (IA) infusion of cisplatin with concurrent radiotherapy with a reduced dose (reduced-RADPLAT) for resectable hypopharyngeal cancer (HPC).
  
  
  METHODS
  Between 1999-2012, 50 patients with stage II-IVA HPC primarily treated by reduced-RADPLAT were analyzed. They were treated by 2-5 courses of IA cisplatin infusion (100 mg per body) with simultaneous systemic infusion of sodium thiosulfate concurrent with conventional radiotherapy (66-70 Gy). After 2003, S-1, an oral fluoropyrimidine, adjuvant chemotherapy was administered to all eligible patients.
  
  
  RESULTS
  During a median follow-up of 48.6 months, the estimated 3- and 5-year overall survival (OS), progression-free survival (PFS), locoregional control, and laryngoesophageal dysfunction-free survival (LEDFS) rates were 76.0% and 62.0%, 58.0% and 50.0%, 66.0% and 62.0%, and 56.0% and 54.0%, respectively. Grade 3 toxicities were observed in 30.0%. No patient had grade 4 or higher toxicities. No patient required tube feeding or tracheotomy at 3 months after treatment. T4-lesions and S-1 administration were significant factors predicting poor and good OS, PFS, and LEDFS, respectively.
authors.affiliation: a Division of Otolaryngology-Head and Neck Surgery , Graduate School of Medical Science, Kanazawa University , Kanazawa , Japan.
authors.forename: Naohiro
authors.initials: N
authors.lastname: Wakisaka
authors.affiliation: a Division of Otolaryngology-Head and Neck Surgery , Graduate School of Medical Science, Kanazawa University , Kanazawa , Japan.
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Hirai
authors.affiliation: a Division of Otolaryngology-Head and Neck Surgery , Graduate School of Medical Science, Kanazawa University , Kanazawa , Japan.
authors.forename: Satoru
authors.initials: S
authors.lastname: Kondo
authors.affiliation: a Division of Otolaryngology-Head and Neck Surgery , Graduate School of Medical Science, Kanazawa University , Kanazawa , Japan.
authors.forename: Mitsuharu
authors.initials: M
authors.lastname: Aga
authors.affiliation: a Division of Otolaryngology-Head and Neck Surgery , Graduate School of Medical Science, Kanazawa University , Kanazawa , Japan.
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Nakanishi
authors.affiliation: a Division of Otolaryngology-Head and Neck Surgery , Graduate School of Medical Science, Kanazawa University , Kanazawa , Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Tsuji
authors.affiliation: a Division of Otolaryngology-Head and Neck Surgery , Graduate School of Medical Science, Kanazawa University , Kanazawa , Japan.
authors.forename: Kazuhira
authors.initials: K
authors.lastname: Endo
authors.affiliation: a Division of Otolaryngology-Head and Neck Surgery , Graduate School of Medical Science, Kanazawa University , Kanazawa , Japan.
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Murono
authors.affiliation: a Division of Otolaryngology-Head and Neck Surgery , Graduate School of Medical Science, Kanazawa University , Kanazawa , Japan.
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Yoshizaki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000379:methods*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000628:therapy*; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin
keywords: Concurrent chemoradiotherapy; S-1 adjuvant chemotherapy; hypopharyngeal cancer; intra-arterial chemotherapy; reduced-RADPLAT